Feasibility and Safety of Treosulfan, Melphalan, and Thiotepa-Based Megachemotherapy with Autologous or Allogeneic Stem Cell Transplantation in Heavily Pretreated Children with Relapsed or Refractory Neuroblastoma

• Published in: Biology of blood and marrow transplantation Vol. 25; no. 9; pp. 1792 - 1797
• Main Authors: Wawrzyniak-Dzierżek, Elżbieta, Gajek, Kornelia, Rybka, Blanka, Ryczan-Krawczyk, Renata, Węcławek-Tompol, Jadwiga, Raciborska, Anna, Mielcarek-Siedziuk, Monika, Frączkiewicz, Jowita, Salamonowicz, Małgorzata, Kałwak, Krzysztof, Rosa, Monika, Ślęzak, Aleksandra, Ussowicz, Marek
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-09-2019
• Subjects: Autologous; Haploidentical; Melphalan; Neuroblastoma; Thiotepa; Treosulfan; Autologous; Neuroblastoma; Haploidentical; Treosulfan; Thiotepa; Melphalan
• ISSN: 1083-8791; 1523-6536
• DOI: 10.1016/j.bbmt.2019.05.006

•Treosulfan-melphalan-thiotepa (TMT) megatherapy is a feasible protocol.•TMT megatherapy has tolerable toxicity in heavily pretreated children with neuroblastoma.•The TMT protocol with addition of fludarabine and antithymocyte globulin can be adapted for allogeneic stem cell transplantation.
The prognosis of resistant or relapsing children with neuroblastoma remains very poor, and the search for new therapies is ongoing. In this analysis, we assessed the toxicity of a treosulfan, melphalan, and thiotepa (TMT) regimen in 17 children with recurrent or refractory neuroblastoma who underwent stem cell transplantation (SCT). For allogeneic SCT, fludarabine and antithymocyte globulin were added. The stem cell source was autologous in 8 patients, haploidentical in 8 patients, and a matched unrelated donor in 1 patient. The reported nonhematologic toxicities included grade 3 mucositis, grade 1 to 3 hypertransaminasemia, and in 3 patients, veno-occlusive disease. No neurologic, cardiac, or dermatologic toxicities were observed. The probability of overall survival (OS) in patients with primary resistance was superior to that in patients with relapsed disease (100% versus 22.6%; P = .046). Post-transplantation dinutuximab beta immunotherapy was associated with superior 5-year OS (66.7% versus 11.4%; P = .0007). The use of an allogeneic donor, previous autologous SCT with busulfan and melphalan, and pretreatment with high-dose metaiodobenzylguanidine therapy demonstrated no effect on outcomes. In 4 patients, TMT megatherapy alone was enough to achieve complete remission. The TMT conditioning regimen was well tolerated in heavily pretreated patients with neuroblastoma. The manageable toxicity and addition of new anticancer drugs with optional post-SCT immunotherapy or chemotherapy support further trials with the TMT regimen in patients with neuroblastoma.